Piramal Pharma shares fell more than 2% in morning trade after US FDA issued an establishment inspection report for a manufacturing facility in Ahmedabad.
In the exchange filing, the company shared, “Kindly refer to our letter dated 12th July, 2024 regarding US FDA Inspection at Piramal Pharma Limited’s manufacturing facility located at Ahmedabad, India, with Zero Form – 483 observations and No Action Indicated (NAI) designation. In furtherance to the aforementioned intimation, this is to inform you that US FDA has issued an EIR for the said manufacturing facility”
As of 9:40 am, Piramal Pharma shares were trading 0.58% down at Rs 221.80 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
